De Souza Laura, Jegatheesan Dev, Chang-Wai Kuinileti, Johnson David W, Campbell Scott B, Viecelli Andrea K, Cho Yeoungjee, Gately Ryan, Isbel Nicole
Department of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Griffith University, Gold Coast, Queensland, Australia.
Intern Med J. 2025 Feb;55(2):277-283. doi: 10.1111/imj.16606. Epub 2024 Dec 19.
The numbers of Māori and Pasifika peoples with kidney failure living in Australia are rising. However, data describing outcomes of those proceeding to transplantation are limited. This study describes clinical outcomes of Māori and Pasifika peoples who received a kidney transplant in Australia.
This study describes clinical outcomes of Maori and Pasifika peoples who received a kidney transplant in Australia.
A retrospective review was conducted of kidney transplant recipients aged ≥18 years receiving their first graft between 1 January 2002 and 31 December 2021, as recorded in the Australia and New Zealand Dialysis and Transplant Registry. The primary outcome was death-censored graft survival. Secondary outcomes included delayed graft function (DGF), rejection and patient survival.
Of 12 543 transplant recipients, mean age was 50 years and the majority identified as male sex. A total of 89 patients identified as Māori and 313 as Pasifika. Māori and Pasifika patients were more likely to have diabetic kidney disease or obesity at time of transplantation (body mass index > 30 kg/m) and be current or former smokers compared to other ethnicities. Times to graft loss were shorter for Māori (adjusted hazard ratio (HR) 2.06, 95% confidence interval (CI) 1.36-3.11) and Pasifika (adjusted HR 1.78, 95% CI 1.39-2.029, P < 0.001) people compared to other ethnicities. The incidences of DGF were significantly higher in the Māori (30%) and Pasifika groups (28%) compared with 22% for other ethnicities (P < 0.005). Overall patient survival was comparable (Māori HR 0.93, 95% CI 0.57-1.49, P = 0.75; Pasifika HR 1.18, Cl 0.88-1.60, P = 0.26).
Times to graft loss for Māori and Pasifika kidney transplant patients were shorter than for other ethnicities.
生活在澳大利亚的患有肾衰竭的毛利人和太平洋岛民人数正在上升。然而，描述那些接受移植者结局的数据有限。本研究描述了在澳大利亚接受肾移植的毛利人和太平洋岛民的临床结局。
本研究描述了在澳大利亚接受肾移植的毛利人和太平洋岛民的临床结局。
对2002年1月1日至2021年12月31日期间在澳大利亚和新西兰透析与移植登记处记录的年龄≥18岁接受首次移植的肾移植受者进行回顾性研究。主要结局是死亡删失的移植物存活。次要结局包括移植肾功能延迟恢复（DGF）、排斥反应和患者存活。
在12543名移植受者中，平均年龄为50岁，大多数为男性。共有89名患者为毛利人，313名患者为太平洋岛民。与其他种族相比，毛利人和太平洋岛民患者在移植时更有可能患有糖尿病肾病或肥胖（体重指数>30kg/m），并且是当前或既往吸烟者。与其他种族相比，毛利人（调整后风险比（HR）2.06，95%置信区间（CI）1.36 - 3.11）和太平洋岛民（调整后HR 1.78，95%CI 1.39 - 2.029，P<0.001）移植物丢失时间更短。毛利人群体（30%）和太平洋岛民群体（28%）的移植肾功能延迟恢复发生率显著高于其他种族的22%（P<0.005）。总体患者存活率相当（毛利人HR 0.93，95%CI 0.57 - 1.49，P = 0.75；太平洋岛民HR 1.18，CI 0.88 - 1.60，P = 0.26）。
毛利人和太平洋岛民肾移植患者的移植物丢失时间比其他种族短。
